What is TLSI's current stock price?

TLSI (TriSalus Life Sciences, Inc.) is currently trading at $3.26 with a market cap of $123.6M.

What sector is TriSalus Life Sciences, Inc. in?

TriSalus Life Sciences, Inc. (TLSI) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is TLSI a good stock to buy?

Analysts have a Buy consensus on TLSI with a price target of $8.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TLSI TriSalus Life Sciences, Inc.

Healthcare

$3.26-5.51%ClosedMarket Cap: $123.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

13.12

P/S

2.75

EV/EBITDA

-3.14

DCF Value

$-113.09

FCF Yield

-16.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.1%

Operating Margin

-62.4%

Net Margin

-60.9%

ROE

162.6%

ROA

-38.5%

ROIC

-47.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$8.9M	$1.5M	$—
Q4 null	$13.2M	$-9.8M	$—
FY null	$45.2M	$-39.2M	$—
Q3 null	$11.6M	$-10.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Lake StreetBuy

2026-05-13

Canaccord GenuityBuy

2026-03-09

Canaccord GenuityBuy

2025-12-17

Trading Activity

Insider Trades

View All

Marshak Richardofficer: Chief Commercial Officer

SellTue May 19

Wahlstrom Matsdirector

BuyMon May 18

Szela Mary Tdirector, officer: CEO and President

BuyMon May 18

Stansky Michael Pdirector

BuyMon May 18

Stansky Michael Pdirector

BuyMon May 18

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.56

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Peers

AVR

PRE